Silk Road Medical Inc (SILK)

$17.42

-0.04

(-0.23%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Silk Road Medical Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 44.43M → 47.27M (in $), with an average increase of 6.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -12.78M → -13.01M (in $), with an average decrease of 1.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 92.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 133.1%

Performance

  • $17.22
    $18.00
    $17.42
    downward going graph

    1.15%

    Downside

    Day's Volatility :4.33%

    Upside

    3.22%

    downward going graph
  • $6.08
    $46.57
    $17.42
    downward going graph

    65.1%

    Downside

    52 Weeks Volatility :86.94%

    Upside

    62.59%

    downward going graph

Returns

PeriodSilk Road Medical IncSector (Health Care)Index (Russel 2000)
3 Months
32.47%
-0.7%
0.0%
6 Months
138.52%
6.6%
0.0%
1 Year
-60.5%
3.7%
-1.5%
3 Years
-66.28%
14.0%
-21.8%

Highlights

Market Capitalization
693.8M
Book Value
$3.86
Earnings Per Share (EPS)
-1.44
Wall Street Target Price
20.17
Profit Margin
-31.47%
Operating Margin TTM
-30.4%
Return On Assets TTM
-13.85%
Return On Equity TTM
-35.39%
Revenue TTM
177.1M
Revenue Per Share TTM
4.57
Quarterly Revenue Growth YOY
18.0%
Gross Profit TTM
100.8M
EBITDA
-56.6M
Diluted Eps TTM
-1.44
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.39
EPS Estimate Next Year
-1.3
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Hold
    6%Buy
    62%Hold
    31%Sell
Based on 16 Wall street analysts offering stock ratings for Silk Road Medical Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
11
11
Hold
10
4
3
Sell
5
2
2

Analyst Forecast

What analysts predicted

Upside of 15.79%

Current $17.42
Target $20.17

Company Financials

FY18Y/Y Change
Revenue
34.6M
↑ 142.37%
Net Income
-37.6M
↑ 94.4%
Net Profit Margin
-108.89%
↑ 26.87%
FY19Y/Y Change
Revenue
63.4M
↑ 83.33%
Net Income
-56.1M
↑ 49.02%
Net Profit Margin
-88.51%
↑ 20.38%
FY20Y/Y Change
Revenue
75.2M
↑ 18.74%
Net Income
-50.4M
↓ 10.14%
Net Profit Margin
-66.98%
↑ 21.53%
FY21Y/Y Change
Revenue
101.5M
↑ 34.89%
Net Income
-50.4M
↑ 0.0%
Net Profit Margin
-49.65%
↑ 17.33%
FY22Y/Y Change
Revenue
138.6M
↑ 36.62%
Net Income
-58.0M
↑ 15.14%
Net Profit Margin
-41.85%
↑ 7.8%
FY23Y/Y Change
Revenue
177.1M
↑ 27.77%
Net Income
-55.7M
↓ 3.92%
Net Profit Margin
-31.47%
↑ 10.38%
Q3 FY22Q/Q Change
Revenue
37.4M
↑ 12.66%
Net Income
-11.4M
↓ 25.89%
Net Profit Margin
-30.53%
↑ 15.89%
Q4 FY22Q/Q Change
Revenue
40.1M
↑ 7.21%
Net Income
-12.6M
↑ 10.39%
Net Profit Margin
-31.44%
↓ 0.91%
Q1 FY23Q/Q Change
Revenue
40.1M
↑ 0.15%
Net Income
-16.0M
↑ 27.08%
Net Profit Margin
-39.89%
↓ 8.45%
Q2 FY23Q/Q Change
Revenue
45.3M
↑ 12.88%
Net Income
-13.5M
↓ 15.78%
Net Profit Margin
-29.77%
↑ 10.12%
Q3 FY23Q/Q Change
Revenue
44.4M
↓ 1.91%
Net Income
-12.8M
↓ 5.16%
Net Profit Margin
-28.78%
↑ 0.99%
Q4 FY23Q/Q Change
Revenue
47.3M
↑ 6.38%
Net Income
-13.0M
↑ 1.74%
Net Profit Margin
-27.52%
↑ 1.26%
FY18Y/Y Change
Total Assets
40.9M
↓ 5.12%
Total Liabilities
54.1M
↓ 61.81%
FY19Y/Y Change
Total Assets
137.4M
↑ 236.1%
Total Liabilities
65.5M
↑ 21.07%
FY20Y/Y Change
Total Assets
179.3M
↑ 30.5%
Total Liabilities
71.8M
↑ 9.62%
FY21Y/Y Change
Total Assets
156.6M
↓ 12.65%
Total Liabilities
77.4M
↑ 7.76%
FY22Y/Y Change
Total Assets
269.7M
↑ 72.19%
Total Liabilities
105.8M
↑ 36.73%
FY23Y/Y Change
Total Assets
265.3M
↓ 1.62%
Total Liabilities
114.2M
↑ 7.89%
Q3 FY22Q/Q Change
Total Assets
162.5M
↓ 0.11%
Total Liabilities
105.3M
↑ 2.58%
Q4 FY22Q/Q Change
Total Assets
269.7M
↑ 65.92%
Total Liabilities
105.8M
↑ 0.44%
Q1 FY23Q/Q Change
Total Assets
259.6M
↓ 3.74%
Total Liabilities
102.0M
↓ 3.63%
Q2 FY23Q/Q Change
Total Assets
263.4M
↑ 1.45%
Total Liabilities
107.9M
↑ 5.77%
Q3 FY23Q/Q Change
Total Assets
260.9M
↓ 0.95%
Total Liabilities
107.7M
↓ 0.12%
Q4 FY23Q/Q Change
Total Assets
265.3M
↑ 1.7%
Total Liabilities
114.2M
↑ 5.97%
FY18Y/Y Change
Operating Cash Flow
-21.7M
↓ 14.09%
Investing Cash Flow
-2.3M
↑ 412.42%
Financing Cash Flow
15.4M
↓ 67.29%
FY19Y/Y Change
Operating Cash Flow
-29.6M
↑ 36.48%
Investing Cash Flow
-70.0M
↑ 2981.76%
Financing Cash Flow
113.8M
↑ 637.53%
FY20Y/Y Change
Operating Cash Flow
-42.1M
↑ 42.07%
Investing Cash Flow
-9.4M
↓ 86.57%
Financing Cash Flow
81.7M
↓ 28.14%
FY21Y/Y Change
Operating Cash Flow
-38.9M
↓ 7.45%
Investing Cash Flow
72.6M
↓ 873.38%
Financing Cash Flow
7.0M
↓ 91.46%
FY22Y/Y Change
Operating Cash Flow
-32.6M
↓ 16.32%
Investing Cash Flow
-162.1M
↓ 323.1%
Financing Cash Flow
139.7M
↑ 1901.99%
Q3 FY22Q/Q Change
Operating Cash Flow
-4.7M
↓ 54.58%
Investing Cash Flow
-32.9M
↑ 48.51%
Financing Cash Flow
1.2M
↓ 95.44%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.7M
↓ 42.36%
Investing Cash Flow
-105.0M
↑ 219.05%
Financing Cash Flow
111.7M
↑ 9110.8%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.1M
↑ 345.93%
Investing Cash Flow
6.1M
↓ 105.82%
Financing Cash Flow
1.1M
↓ 99.01%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.6M
↓ 62.0%
Investing Cash Flow
-19.2M
↓ 413.76%
Financing Cash Flow
1.6M
↑ 43.42%

Technicals Summary

Sell

Neutral

Buy

Silk Road Medical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Silk Road Medical Inc
Silk Road Medical Inc
2.77%
138.52%
-60.5%
-66.28%
-48.63%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Silk Road Medical Inc
Silk Road Medical Inc
NA
NA
NA
-1.39
-0.35
-0.14
NA
3.86
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Silk Road Medical Inc
Silk Road Medical Inc
Hold
$693.8M
-48.63%
NA
-31.47%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • Wasatch Advisors Inc.

    10.34%

  • Goldman Sachs Group Inc

    10.27%

  • BlackRock Inc

    7.69%

  • Capital World Investors

    7.57%

  • Vanguard Group Inc

    7.38%

  • Jefferies Financial Group Inc

    4.87%

Corporate Announcements

  • Silk Road Medical Inc Earnings

    Silk Road Medical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

silk road medical, inc. is a privately held company located in sunnyvale, california, dedicated to preventing the devastating burden of stroke through surgical innovation. the company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. for more information on the company, visit our website at http://silkroadmed.com/. the transcarotid artery revascularization (tcar) procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. th

Organization
Silk Road Medical Inc
Employees
474
CEO
Mr. Lucas W. Buchanan
Industry
Medical Specialties

Discover More

FAQs